imt-2021-0013 - Supplementary Material - Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models
Supplementary Figure 1. Ruxolitinib effect on a fully mismatched GvHD mouse model. Animals were weighed daily and their percent body weight change was measured from day 0 until the completion of the study on day 36. The AUC to determine body weight change was calculated from days 0–35 to enable effective comparison of groups by statistical analyses.
**p < 0.01 versus the vehicle group.
AUC: area under the curve; GvHD: graft-versus-host disease; SEM: standard error of the mean.